Mink Therapeutics Inc
NASDAQ:INKT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Mink Therapeutics Inc
Other Non-Cash Items
Mink Therapeutics Inc
Other Non-Cash Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Non-Cash Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Mink Therapeutics Inc
NASDAQ:INKT
|
Other Non-Cash Items
$3.1m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Non-Cash Items
$9.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
2%
|
CAGR 10-Years
25%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Non-Cash Items
$2.5B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Non-Cash Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Non-Cash Items
$1.2B
|
CAGR 3-Years
26%
|
CAGR 5-Years
41%
|
CAGR 10-Years
17%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Non-Cash Items
$183.1m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-10%
|
|
Mink Therapeutics Inc
Glance View
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company is headquartered in New York City, New York and currently employs 33 full-time employees. The company went IPO on 2021-10-15. The firm is specialized in discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (NK) cells. iNKT cells offer therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress graft-versus-host-disease (GvHD). The firm offers platform, which is designed for reproducible manufacturing for off-the-shelf delivery. Its product candidate, AGENT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy that is in multiple Phase I clinical trials, which is used for the treatment of multiple myeloma.
See Also
What is Mink Therapeutics Inc's Other Non-Cash Items?
Other Non-Cash Items
3.6m
USD
Based on the financial report for Dec 31, 2023, Mink Therapeutics Inc's Other Non-Cash Items amounts to 3.6m USD.
What is Mink Therapeutics Inc's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 3Y
-16%
Over the last year, the Other Non-Cash Items growth was 1 397%. The average annual Other Non-Cash Items growth rates for Mink Therapeutics Inc have been -16% over the past three years .